tetano
Editor, Senior Moderator
Int J Clin Pharmacol Ther. 2018 Dec 11. doi: 10.5414/CP203366. [Epub ahead of print]
[h=1]Comparison of the effects of peramivir and oseltamivir on the rise in platelet count in patients with or without proven influenza .[/h] Kim YG, Ko SY, Lee SW.
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count.
[h=4]MATERIALS AND METHODS:[/h] Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed. The analysis included 461 patients with platelet counts available; the patients were divided into three groups: patients with proven influenza treated with peramivir (n = 305); those treated with peramivir without proven influenza (n = 83), and those with proven influenza treated with oseltamivir (n = 73).
[h=4]RESULTS:[/h] Patients treated with peramivir did not show an increase in platelet count from the baseline count, regardless of proven influenza (from 263.4 ? 109/L to 267.4 ? 109/L; 9 = 0.410) or not (from 257.1 ? 109/L to 255.4 ? 109/L; p = 0.873); wheeras for patients treated with oseltamivir, a significant increase above the baseline was found (from 223.3 ? 109/L to 249.9 ? 109/L; p = 0.016), although it was transient.
[h=4]CONCLUSION:[/h] Peramivir and oseltamivir appear to have different effects on patient platelet count when administered at the recommended doses. .
PMID: 30526812 DOI: 10.5414/CP203366
[h=1]Comparison of the effects of peramivir and oseltamivir on the rise in platelet count in patients with or without proven influenza .[/h] Kim YG, Ko SY, Lee SW.
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] Neuraminidase (sialidase) inhibitors are considered to delay platelet clearance through the inhibition of platelet desialylation. A novel neuraminidase inhibitor, peramivir, was recently approved for intravenous administration by the US FDA. We aimed to compare the effects of peramivir and oseltamivir on patient platelet count.
[h=4]MATERIALS AND METHODS:[/h] Consecutive patients who were treated with peramivir or tested positive for influenza between January 2015 and December 2017 were analyzed. The analysis included 461 patients with platelet counts available; the patients were divided into three groups: patients with proven influenza treated with peramivir (n = 305); those treated with peramivir without proven influenza (n = 83), and those with proven influenza treated with oseltamivir (n = 73).
[h=4]RESULTS:[/h] Patients treated with peramivir did not show an increase in platelet count from the baseline count, regardless of proven influenza (from 263.4 ? 109/L to 267.4 ? 109/L; 9 = 0.410) or not (from 257.1 ? 109/L to 255.4 ? 109/L; p = 0.873); wheeras for patients treated with oseltamivir, a significant increase above the baseline was found (from 223.3 ? 109/L to 249.9 ? 109/L; p = 0.016), although it was transient.
[h=4]CONCLUSION:[/h] Peramivir and oseltamivir appear to have different effects on patient platelet count when administered at the recommended doses. .
PMID: 30526812 DOI: 10.5414/CP203366